X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (2) 2
6 inhibitor (1) 1
acquired-resistance (1) 1
adenocarcinoma (1) 1
adult (1) 1
amplification (1) 1
antineoplastic agents - therapeutic use (1) 1
article (1) 1
bgj398 (1) 1
bile duct neoplasms - drug therapy (1) 1
bile duct neoplasms - genetics (1) 1
bile duct neoplasms - pathology (1) 1
cancer drug-resistance (1) 1
cdk4 (1) 1
cdk4/6 inhibitor (1) 1
cell free dna (1) 1
cholangiocarcinoma - drug therapy (1) 1
cholangiocarcinoma - genetics (1) 1
cholangiocarcinoma - pathology (1) 1
circulating tumor dna - genetics (1) 1
colorectal-cancer (1) 1
crizotinib (1) 1
drug resistance, neoplasm - genetics (1) 1
female (1) 1
fibroblast growth factor receptor (1) 1
gefitinib resistance (1) 1
gene fusion (1) 1
hepatocyte growth-factor (1) 1
heterogeneity (1) 1
humans (1) 1
index medicus (1) 1
intrahepatic cholangiocarcinoma (1) 1
kinase inhibition (1) 1
landscape (1) 1
lee011 (1) 1
male (1) 1
middle aged (1) 1
musculoskeletal diseases (1) 1
mutation (1) 1
mutations (1) 1
nvp-bgj398 (1) 1
phase-ii (1) 1
phenylurea compounds - therapeutic use (1) 1
preclinical (1) 1
protein (1) 1
pyrimidines - therapeutic use (1) 1
receptor, fibroblast growth factor, type 2 - antagonists & inhibitors (1) 1
receptor, fibroblast growth factor, type 2 - chemistry (1) 1
receptor, fibroblast growth factor, type 2 - genetics (1) 1
receptor, fibroblast growth factor, type 3 - chemistry (1) 1
receptor, fibroblast growth factor, type 3 - metabolism (1) 1
research paper (1) 1
resistance mutations (1) 1
ribociclib (1) 1
selectivity (1) 1
sensitivity (1) 1
targeted therapy (1) 1
transcription factor tfiiia - genetics (1) 1
tumors (1) 1
tyrosine kinase (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 2019, Volume 25, Issue 10, pp. 3164 - 3175
Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical trials, both as a single agent and in combination. Here, we describe... 
KINASE INHIBITION | AMPLIFICATION | ONCOLOGY | ADENOCARCINOMA | HEPATOCYTE GROWTH-FACTOR | ACQUIRED-RESISTANCE | SENSITIVITY | CRIZOTINIB | PHASE-II | MUTATIONS | GEFITINIB RESISTANCE
Journal Article
Cancer Discovery, ISSN 2159-8274, 03/2017, Volume 7, Issue 3, pp. 252 - 263
Journal Article
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 2346 - 2346
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 81, pp. 35226 - 35240
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6... 
LEE011 | Ribociclib | Selectivity | Preclinical | CDK4/6 inhibitor
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.